Compare AAPG & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAPG | OLMA |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2025 | 2020 |
| Metric | AAPG | OLMA |
|---|---|---|
| Price | $27.68 | $26.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $48.50 | $40.50 |
| AVG Volume (30 Days) | 4.1K | ★ 2.9M |
| Earning Date | 03-26-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,524,554.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $368.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.50 | $2.86 |
| 52 Week High | $48.45 | $36.26 |
| Indicator | AAPG | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 38.05 | 50.90 |
| Support Level | $25.83 | $25.85 |
| Resistance Level | $29.37 | $36.26 |
| Average True Range (ATR) | 0.91 | 2.77 |
| MACD | -0.18 | -1.22 |
| Stochastic Oscillator | 16.46 | 6.25 |
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.